Physician profile
Michael Taccona
NPI 1861223570
$3,338.24
in general payments reported to CMS, 2019-2025
22 companies · $2,619 in 2025
The $2,619 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $719 · 2025: $2,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753 · Consulting Fee: $500 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.25 |
| Consulting Fee | $500.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $681.86 | 2024-2025 | Nanoknife |
| Astrazeneca Pharmaceuticals Lp | $500.00 | 2025 | Imfinzi |
| Astellas Pharma US INC | $275.28 | 2024-2025 | Xtandi |
| Janssen Biotech, INC. | $257.00 | 2024-2025 | Erleada |
| Sumitomo Pharma America, INC. | $233.25 | 2024-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $193.00 | 2024-2025 | |
| Tolmar, INC. | $171.05 | 2024-2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $145.41 | 2024-2025 | |
| Abbvie INC. | $140.31 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $93.02 | 2025 | Adstiladrin |
| 180 Medical, INC. | $80.81 | 2024-2025 | Gentlecath |
| Teleflex LLC | $76.26 | 2024-2025 | Urolift |
| Progenics Pharmaceuticals, INC. | $74.60 | 2025 | |
| Dendreon Pharmaceuticals LLC | $73.50 | 2025 | Provenge |
| Lantheus Medical Imaging, INC. | $70.16 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $66.67 | 2024-2025 | Spaceoar Vue System - 10ml |
| Azurity Pharmaceuticals, INC. | $45.46 | 2025 | Azmiro |
| Procept Biorobotics Corporation | $45.40 | 2025 | |
| Profound Medical Corp. | $40.36 | 2025 | Tulsa-Pro |
| Endo USA, INC. | $32.64 | 2024-2025 | Xiaflex |
| Abc Home Medical Supply, INC. | $27.93 | 2025 | |
| Antares Pharma, INC. | $14.27 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Taccona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.